keyboard_arrow_up
HTF Market Intelligence

Worldwide NASH (Non-alcoholic Steatohepatitis) biomarkers Market to witness astonishing growth of 31% in next coming years

HTF Market Report released a new research document of 185 pages on industry titled as ‘NASH (Non-alcoholic Steatohepatitis) biomarkers – Global Market Outlook (2017-2023)’ with detailed analysis, Competitive landscape, forecast and strategies. The study covers geographic analysis that includes regions like North America, Europe, Asia Pacific, South America, Middle East & Africa and important players/vendors such as Allergan Plc, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb Company, etc… The report will help you gain market insights, future trends and growth prospects for forecast period of 2017-2023


Request a sample report @ https://www.htfmarketreport.com/sample-report/770325-nash-non-alcoholic-steatohepatitis-biomarkers-global-market



According to Research Analyst, the Global NASH (Non-Alcoholic Steatohepatitis) Biomarkers market is expected to grow from $202.12 million in 2016 to reach $1,350.23 million by 2023 with a CAGR of 31.2%. 


Rising demand for noninvasive diagnostic tools matched with growing levels of patient awareness is likely to augment the growth of NASH biomarkers market over the forecast period. Furthermore, growing prevalence of chronic liver conditions is expected to upsurge demand for noninvasive diagnostic tools. On the contrary, huge price and invasiveness, ensued in changing the taste for noninvasive biomarkers is expected to limit the market growth over the forecast period.


Biomarkers are commonly proteins detected in the blood, urine or other body fluids that are either raised by the tumor itself. Serum Biomarker should be measured at a low cost, by a widely usable assay with reproducible outcomes in a specimen that is comfortable to access. The serum biomarkers have the ability to deliver efficient results. Apoptosis markers follow this lead closely. Hospitals and diagnostic laboratories are likely to be rising in requirement for non-invasive NASH diagnostic and monitoring instruments at the ongoing tests by pharmaceutical manufacturers and CRO.

North America holds the largest market share due to different reasons like rising prevalence of infectious diseases, cardiovascular diseases & cancer, rising R&D activities from key players, and favorable government initiatives. Asia Pacific is expected to become the fastest growing market owing to enlargement of key market participants. There is a substantial rise in R&D spending for biomarkers from the countries like China, India and Japan. In addition, increasing demand for biomarkers among end-users and rising number of CROs are factors favoring the market growth in this region.


Some of the key players in global NASH (Non-Alcoholic Steatohepatitis) Biomarkers market include Allergan Plc, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb Company, Dainippon Sumitomo Pharma (DSP), Enzo Biochem, GENFIT SA, Gilead Sciences, Inc. (GILD), Intercept Pharmaceuticals, Novartis AG, Novo Nordisk A/S, Pfizer Inc, Prometheus Laboratories Corp, Raptor Pharmaceutical Corp and Siemens Heathcare Pvt. Ltd.


Types Covered:

• Hepatic fibrosis biomarkers

• Serum biomarkers

• Oxidative stress biomarkers

• Apoptosis biomarkers

• Other Biomarkers Types


Application Types Covered:

• Hospitals

• Pharma & CRO Industry

• Academic Research Institutes

• Diagnostic Labs


Regions Covered:

• North America

o US

o Canada

o Mexico

• Europe

o Germany

o UK

o Italy

o France

o Spain

o Rest of Europe

• Asia Pacific

o Japan

o China

o India

o Australia

o New Zealand

o Rest of Asia Pacific

• South America

o Argentina

o Brazil

o Chile

o Rest of South America

• Middle East & Africa

o Saudi Arabia

o UAE

o Qatar

o South Africa

o Rest of Middle East & Africa


What our report offers:

– Market share assessments for the regional and country level segments

– Market share analysis of the top industry players

– Strategic recommendations for the new entrants

– Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets

– Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)

– Strategic recommendations in key business segments based on the market estimations

– Competitive landscaping mapping the key common trends

– Company profiling with detailed strategies, financials, and recent developments

– Supply chain trends mapping the latest technological advancements


Get Customization in the Report, Enquire Now @ https://www.htfmarketreport.com/enquiry-before-buy/770325-nash-non-alcoholic-steatohepatitis-biomarkers-global-market


1 Executive Summary


2 Preface

2.1 Abstract

2.2 Stake Holders

2.3 Research Scope

2.4 Research Methodology

2.4.1 Data Mining

2.4.2 Data Analysis

2.4.3 Data Validation

2.4.4 Research Approach

2.5 Research Sources

2.5.1 Primary Research Sources

2.5.2 Secondary Research Sources

2.5.3 Assumptions

3 Market Trend Analysis

3.1 Introduction

3.2 Drivers

3.3 Restraints

3.4 Opportunities

3.5 Threats

3.6 End User Analysis

3.7 Emerging Markets

3.8 Futuristic Market Scenario

4 Porters Five Force Analysis

4.1 Bargaining power of suppliers

4.2 Bargaining power of buyers

4.3 Threat of substitutes

4.4 Threat of new entrants

4.5 Competitive rivalry

5 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market, By Type

5.1 Introduction

5.2 Hepatic fibrosis biomarkers

5.3 Serum biomarkers

5.4 Oxidative stress biomarkers


….Continued


View Detailed Table of Content @ https://www.htfmarketreport.com/reports/770325-nash-non-alcoholic-steatohepatitis-biomarkers-global-market


Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.


Buy this report @ https://www.htfmarketreport.com/buy-now?format=1&report=770325



Contact Us:

CRAIG FRANCIS (PR & Marketing Manager)

sales@htfmarketreport.com

Ph: +1 (206) 317 1218